Based on the positive clinical results of the DESTINY-Breast04 trial, a precise differentiation of HER2 expression will become increasingly important, in particular for patients with breast cancer in an advanced stage (Lee and Park 2022; Modi et al. 2022). The gene discussed is ERBB2; the disease is breast carcinoma.